-
Electronic (PDF)
-
Site License
-
Enterprisewide
Parkinson's Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020
GlobalData, January 2012, Pages: 318
Parkinson's Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020
Summary
GlobalData, the industry analysis specialist, has released its new report, “Parkinson's Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the global Parkinson’s Disease (PD) therapeutics market. It provides comprehensive market information, highlighting the treatment guidelines and identifying and analyzing the key trends shaping and driving the global market. It analyzes treatment usage patterns and provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the market leaders. The report provides valuable insights into the pipeline products and quantifies the unmet need within the global PD therapeutics market and as well as in the individual markets of the US and the top five countries in Europe, highlighting opportunities for future players.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
In 2011, the global Parkinson’s Disease (PD) therapeutics market, which includes the key markets of the US, Japan, Germany, the UK, France, Italy, Spain, Brazil, China, India and Russia was estimated to be worth $2,992m. During the period 2002-2011, the global PD therapeutics market grew at a Compound Annual Growth Rate (CAGR) of 5.8%. GlobalData analysis shows that the market size was primarily driven by two key parameters: the increase in PD prevalence due to the increase in the aging population in the 11 key markets and the increasing cost of therapy. In 2011, the market registered a decline in the market valuations due to the entry of generics for Mirapex (pramipexole) and higher preference for generic ropinirole.The global PD therapeutics market is primarily served by levodopa, dopamine agonists, Monoamine Oxidase Inhibitors (MAO-BI) and Catechol-O-Methyltransferase (COMT) inhibitors. The market is dominated by branded products such as Boehringer Ingelheim’s Mirapex/Mirapexin/Sifrol/MirapexER/MirapexinER (pramipexole), GlaxoSmithKline’s (GSK) Requip/RequipXL(ropinirole),Orion/Novartis’ Stalevo/Comtan (carbidopa/levodopa/entacapone) and Teva/Lundbeck’s Azilect/Agilect (rasagiline). In addition, a large number of generics are also available in this market. The global PD therapeutics market is expected to grow at a modest CAGR of 2.2% and is forecast to reach $3,650m by 2020. The modest growth rate has been attributed to patent expiries of the major drugs, the subsequent entry of generics and the weak late stage developmental pipeline.
Scope
The scope of the report includes -
- An overview of the PD therapeutics market which includes epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines.
- Annualized global PD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2002-2011 and forecast to 2020.
- Geographies covered in this report include the US, the UK, Italy, Spain, Germany, France, Japan, Brazil, Russia, India and China.
- Insightful review of the key industry drivers, restraints and challenges and predicted impact of key events.
- Competitor assessment including drug launch analysis and drug sales forecasts.
- Product profiles covering efficiency, safety, clinical study details, annual cost, regulatory approvals and drug sales forecast.
- Analysis of unmet need in the market and target product profiles including opportunities for target products.
- Technology trends analytic framework to assess the strength of the pipeline.
- Pipeline analysis data giving a split across different Phases, mechanisms of action and emerging trends.
- Clinical trials mapping of trials for the PD therapeutics market in different regions.
- An overview of the most promising drugs with clinical study details, efficacy, safety, collaboration agreements, marketing rights, and launch analysis and drug sales forecasts to 2020.
- Analysis of the current and future market competition in the global PD therapeutics market therapeutics market and company profiles including business description, financial overview and SWOT analysis. Key future market players covered include Merck &Co, Impax Laboratories, Acadia Pharmaceuticals, Newron Pharmaceuticals and Abbott Laboratories.
- Analysis of licensing agreements during 2010-2011 in the PD therapeutics market therapeutics market. The M&A analysis covers M&A deals.
- Strategic assessment of the market through market impact analysis, future market scenario and company analysis.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop business strategies and perform superior market quantification analysis by:
- Understanding the trends shaping and driving the global PD therapeutics market.
- Understanding physician treatment preferences across the treatment flow.
- Accessing market sizing, forecasts and quantified growth opportunities in the global PD therapeutics market therapeutics market until 2020.
- Quantifying patient population in the global PD therapeutics market therapeutics market to better design product pricing and launch plans.
- Drive revenues, formulate effective sales and marketing strategies and gain in-depth understanding of the competitive landscape by:
- Performing benchmarking analysis and growth opportunities against currently marketed products.
- Identifying market entry points based on safety, efficacy, and pricing parameters.
- Assessing competitiveness of products in market by understanding the strength and weakness of current competition.
- Develop and design your in-licensing and out-licensing strategies by:
- Taking a comprehensive look at the disease pipeline and identifying the most promising paradigm shifting products.
- Assessing strength of pipeline based on first-in-class, me-too, generic and lifecycle management of products.
- Track drug sales in the global PD therapeutics market therapeutics market from 2002-2020.
- Identify the emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present the best opportunities for consolidation, investments and strategic partnerships.
- What is the next big thing in the global PD therapeutics market therapeutics market landscape? Identify, understand and capitalize.
Keywords
Market forecast, revenues, unmet need, drivers, barriers, pharma, clinical trials, marketed products, pipeline, promising drugs, future players, key companies, strategic competitor assessment, market characterization, implications for future market, mechanism of action, oncology, cancer, treatment guideline, target product profile, clinician's endpoints, disease overview, colorectal cancer drug sales, US colorectal cancer market, UK colorectal cancer market, France colorectal cancer market, Germany colorectal cancer market, Italy colorectal cancer market, Spain colorectal cancer market, Japan colorectal cancer market, BRIC colorectal cancer market, Brazil, Russia, India, China
1
1
1.1 List of Tables
1.2 List of Figures
2 Parkinson’s Disease Therapeutics - Disease Overview
2.1 Overview
2.2 Epidemiology
2.3 Etiology
2.3.1 Genetic Factors
2.3.2 Environmental Factors
2.4 Pathophysiology of Parkinson’s Disease
2.5 Symptoms
2.5.1 Primary Motor Symptoms
2.5.2 Secondary Motor Symptoms
2.5.3 Non Motor Symptoms
2.6 Risk Factors
2.7 Prognosis
2.8 Diagnosis
2.8.1 Medical History/Clinical and Neurological Examination
2.8.2 Imaging Techniques
2.9 Treatment
2.9.1 Drug Therapy
2.9.2 Surgery
2.9.3 Rehabilitation Therapy
3 Parkinson’s Disease Therapeutics - Market Characterization
3.1 Global
3.1.1 Market Size
3.1.2 Drivers and Barriers
3.1.3 Forecasts
3.1.4 Drug Sales
3.2 The US
3.2.1 Market Size
3.2.2 Drivers and Barriers
3.2.3 Forecasts
3.2.4 Drug Sales
3.2.5 Pricing and Reimbursements
3.3 The UK
3.3.1 Market Size
3.3.2 Drivers and Barriers
3.3.3 Impact on the Market
3.3.4 Forecasts
3.3.5 Drug Sales
3.3.6 Pricing and Reimbursements
3.4 Germany
3.4.1 Market Size
3.4.2 Drivers and Barriers
3.4.3 Impact on the Market
3.4.4 Forecasts
3.4.5 Drug Sales
3.4.6 Pricing and Reimbursements
3.5 France
3.5.1 Market Size
3.5.2 Drivers and Barriers
3.5.3 Impact on the Market
3.5.4 Forecasts
3.5.5 Drug Sales
3.5.6 Pricing & Reimbursements
3.6 Italy
3.6.1 Market Size
3.6.2 Drivers and Barriers
3.6.3 Impact on the Market
3.6.4 Forecasts
3.6.5 Drug Sales
3.6.6 Pricing and Reimbursements
3.7 Spain
3.7.1 Market Size
3.7.2 Drivers and Barriers
3.7.3 Impact on the Market
3.7.4 Forecasts
3.7.5 Drug Sales
3.7.6 Pricing and Reimbursements
3.8 Japan
3.8.1 Market Size
3.8.2 Drivers and Barriers
3.8.3 Impact on the Market
3.8.4 Forecasts
3.8.5 Drug Sales
3.8.6 Pricing and Reimbursements
3.9 Brazil
3.9.1 Market Size
3.9.2 Drivers and Barriers
3.9.3 Impact on the Market
3.9.4 Forecasts
3.9.5 Future Impact
3.10 India
3.10.1 Market Size
3.10.2 Drivers and Barriers
3.10.3 Impact on the Market
3.10.4 Forecasts
3.10.5 Future Impact
3.11 China
3.11.1 Market Size
3.11.2 Drivers and Barriers
3.11.3 Impact on the Market
3.11.4 Forecasts
3.11.5 Future Impact
3.12 Russia
3.12.1 Market Size
3.12.2 Drivers and Barriers
3.12.3 Impact on the Market
3.12.4 Forecasts
3.12.5 Future Impact
3.13 Key Takeaway
4 Parkinson’s Disease Therapeutics - Opportunity and Unmet Need
4.1 Key Takeaway
5 Parkinson’s Disease Therapeutics - Competitive Assessment
5.1 Overview
5.2 Strategic Competitor Assessment
5.3 Product Profile for the Major Marketed Products in the PD Market
5.3.1 Stalevo (levodopa, carbidopa, entacapone)
5.3.2 Requip XL (ropinirole XL)
5.3.3 Azilect (rasagiline mesylate)
5.3.4 Mirapex ER (pramipexole dihydrochloride)
5.3.5 Comtan (entacapone)
5.3.6 Neupro (rotigotine transdermal patch)
5.3.7 Apokyn (apomorphine hydrochloride)
5.4 Key Takeaway
6 PD Therapeutics - Pipeline Assessment
6.1 Overview
6.2 Strategic Pipeline Assessment
6.2.1 Technology Trends Analytic Framework
6.3 PD Therapeutics - Promising Drugs under Clinical Development
6.4 Molecule Profile for Promising Drugs under Clinical Development
6.4.1 IPX066 (Impax Pharmaceuticals)
6.4.2 Safinamide (Newron Pharmaceuticals)
6.4.3 Preladenant (Merck & Co. Inc)
6.4.4 Pimavanserin (Acadia Pharmaceutical)
6.4.5 Duodopa (Abbott Laboratories)
6.5 PD Therapeutics Market - Clinical Pipeline by Mechanism of Action
6.6 PD Pipeline - Pipeline by Phases of Development
6.6.1 PD Therapeutics - Phase III Clinical Pipeline
6.6.2 PD Therapeutics - Phase II Clinical Pipeline
6.6.3 PD Therapeutics - Phase I Clinical Pipeline
6.6.4 PD Therapeutics - Pre-Clinical Pipeline
6.7 Future Parkinson’s Disease Therapies
6.8 Key Takeaway
7 PD Therapeutics - Clinical Trials Mapping
7.1 Clinical Trials
7.1.1 Clinical Trials by Status
7.1.2 Clinical Trials by Country
7.1.3 Clinical Trials by Phase
7.1.4 Clinical Trials by Sponsor Type
7.1.5 Clinical Trials - Leading Sponsors
7.1.6 Clinical Trials - Leading Company Sponsors by Phase
8 PD Therapeutics - Patient Recruitment
9 PD Therapeutics - Implications for Future Market Competition
10 PD Therapeutics - Future Market Players
10.1 Introduction
10.2 Abbott Laboratories
10.2.1 Business Description
10.2.2 Financial Overview
10.2.3 SWOT Analysis
10.2.4 CNS Pipeline
10.3 ACADIA Pharmaceuticals Inc
10.3.1 Business Description
10.3.2 Financial Overview
10.3.3 SWOT Analysis
10.3.4 Acadia Pharmaceutical CNS Pipeline
10.4 Merck & Co.
10.4.1 Business Description
10.4.2 Financial Overview
10.4.3 SWOT Analysis
10.4.4 Merck CNS Pipeline
10.5 IMPAX Laboratories
10.5.1 Business Description
10.5.2 Financial Overview
10.5.3 SWOT Analysis
10.5.4 CNS Pipeline
10.6 Newron Pharmaceuticals S.p.A
10.6.1 Business Description
10.6.2 Financial Overview
10.6.3 SWOT Analysis
10.6.4 CNS Pipeline
11 PD Therapeutics - Partners in Research and Development
11.1 Partners in Research and Development
11.2 Licensing Agreements
11.2.1 Licensing Agreements
11.2.2 Terminated Licensing Agreements
11.3 Mergers & Acquisition Analysis
11.3.1 Key Highlights
11.4 Expert Opinion
11.4.1 US
11.4.2 France
11.4.3 Germany
11.4.4 UK
11.4.5 Italy
11.4.6 India
12 PD Therapeutics - Appendix
12.1 Definitions
12.2 Abbreviations
12.3 Research Methodology
12.3.1 Coverage
12.3.2 Secondary Research
12.3.3 Forecasting
12.3.4 Primary Research
12.3.5 Expert Panel Validation
12.4 Contact Us
12.5 Disclaimer
12.6 Bibliography
1.1 List of Tables
Table 1: PD Prescription Medication Dosage
Table 2: PD Therapeutics Market, Global, Sales Value ($m), 2002-2011
Table 3: PD Therapeutics Market, Global, Sales Value ($m) by Country, 2002-2011
Table 4: PD Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2011
Table 5: PD Therapeutics Market, Global, Patient Volume (Absolute), 2002-2011
Table 6: PD Therapeutics Market, Global, Treatment Usage Patterns, 2002-2011
Table 7: PD Therapeutics Market, Global, Sales Value ($m), 2011-2020
Table 8: PD Therapeutics Market, Global, Sales Value ($m) by Country, 2011-2020
Table 9: PD Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2020
Table 10: PD Therapeutics Market, Global, Patient Volume (Absolute), 2011-2020
Table 11: PD Therapeutics Market, Global, Treatment Usage Patterns, 2011-2020
Table 12: PD Therapeutics Market, Global, Drug Sales ($m), 2002-2011
Table 13: PD Therapeutics Market, Global, Drug Sales ($m), 2011-2020
Table 14: PD Therapeutics Market, The US, Sales Value ($m), 2002-2011
Table 15: PD Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2011
Table 16: PD Therapeutics Market, The US, Patient Volume (Absolute), 2002-2011
Table 17: PD Therapeutics Market, The US, Treatment Usage Patterns, 2002-2011
Table 18: PD Therapeutics Market, The US, Sales Value ($m), 2011-2020
Table 19: PD Therapeutics Market, The US, Annual Cost of Therapy ($), 2011-2020
Table 20: PD Therapeutics Market, The US, Patient Volume (Absolute), 2011-2020
Table 21: PD Therapeutics Market, The US, Treatment Usage Patterns, 2011-2020
Table 22: PD Therapeutics Market, The US, Drug Sales ($m), 2002-2011
Table 23: PD Therapeutics Market, The US, Drug Sales ($m), 2011-2020
Table 24: PD Therapeutics Market, The UK, Sales Value ($m), 2002-2011
Table 25: PD Therapeutics Market, The UK, Annual Cost of Therapy ($), 2002-2011
Table 26: PD Therapeutics Market, The UK, Patient Volume (Absolute), 2002-2011
Table 27: PD Therapeutics Market, The UK, Treatment Usage Patterns, 2002-2011
Table 28: PD Therapeutics Market, The UK, Sales Value ($m), 2011-2020
Table 29: PD Therapeutics Market, The UK, Annual Cost of Therapy ($), 2011-2020
Table 30: PD Therapeutics Market, The UK, Patient Volume (Absolute), 2011-2020
Table 31: PD Therapeutics Market, The UK, Treatment Usage Patterns, 2011-2020
Table 32: PD Therapeutics Market, The UK, Drug Sales ($m), 2002-2011
Table 33: PD Therapeutics Market, The UK, Drug Sales ($m), 2011-2020
Table 34: PD Therapeutics Market, Germany, Sales Value ($m), 2002-2011
Table 35: PD Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002-2011
Table 36: PD Therapeutics Market, Germany, Patient Volume (Absolute), 2002-2011
Table 37: PD Therapeutics Market, Germany, Treatment Usage Patterns, 2002-2011
Table 38: PD Therapeutics Market, Germany, Sales Value ($m), 2011-2020
Table 39: PD Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011-2020
Table 40: PD Therapeutics Market, Germany, Patient Volume (Absolute), 2011-2020
Table 41: PD Therapeutics Market, Germany, Treatment Usage Patterns, 2011-2020
Table 42: PD Therapeutics Market, Germany, Drug Sales ($m), 2002-2011
Table 43: PD Therapeutics Market, Germany, Drug Sales ($m), 2011-2020
Table 44: PD Therapeutics Market, France, Sales Value ($m), 2002-2011
Table 45: PD Therapeutics Market, France, Annual Cost of Therapy ($), 2002-2011
Table 46: PD Therapeutics Market, France, Patient Volume (Absolute), 2002-2011
Table 47: PD Therapeutics Market,France, Treatment Usage Patterns, 2002-2011
Table 48: PD Therapeutics Market, France, Sales Value ($m), 2011-2020
Table 49: PD Therapeutics Market, France, Annual Cost of Therapy ($), 2011-2020
Table 50: PD Therapeutics Market, France, Patient Volume (Absolute), 2011-2020
Table 51: PD Therapeutics Market, France, Treatment Usage Patterns, 2011-2020
Table 52: PD Therapeutics Market, France, Drug Sales ($m), 2002-2011
Table 53: PD Therapeutics Market, France, Drug Sales ($m), 2011-2020
Table 54: PD Therapeutics Market, Italy, Sales Value ($m), 2002-2011
Table 55: PD Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002-2011
Table 56: PD Therapeutics Market, Italy, Patient Volume (Absolute), 2002-2011
Table 57: PD Therapeutics Market, Italy, Treatment Usage Patterns, 2002-2011
Table 58: PD Therapeutics Market, Italy, Sales Value ($m), 2011-2020
Table 59: PD Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011-2020
Table 60: PD Therapeutics Market, Italy, Patient Volume (Absolute), 2011-2020
Table 61: PD Therapeutics Market, Italy, Treatment Usage Patterns, 2011-2020
Table 62: PD Therapeutics Market, Italy, Drug Sales ($m), 2002-2011
Table 63: PD Therapeutics Market, Italy, Drug Sales ($m), 2011-2020
Table 64: PD Therapeutics Market, Spain, Sales Value ($m), 2002-2011
Table 65: PD Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002-2011
Table 66: PD Therapeutics Market, Spain, Patient Volume (Absolute), 2002-2011
Table 67: PD Therapeutics Market, Spain, Treatment Usage Patterns, 2002-2011
Table 68: PD Therapeutics Market, Spain, Sales Value ($m), 2011-2020
Table 69: PD Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011-2020
Table 70: PD Therapeutics Market, Spain, Patient Volume (Absolute), 2011-2020
Table 71: PD Therapeutics Market, Spain, Treatment Usage Patterns, 2011-2020
Table 72: PD Therapeutics Market,Spain, Drug Sales ($m), 2002-2011
Table 73: PD Therapeutics Market,Spain, Drug Sales ($m), 2011-2020
Table 74: PD Therapeutics Market, Japan, Sales Value ($m), 2002-2011
Table 75: PD Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2011
Table 76: PD Therapeutics Market, Japan, Patient Volume (Absolute), 2002-2011
Table 77: PD Therapeutics Market, Japan, Treatment Usage Patterns, 2002-2011
Table 78: PD Therapeutics Market, Japan, Sales Value ($m), 2011-2020
Table 79: PD Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2020
Table 80: PD Therapeutics Market, Japan, Patient Volume (Absolute), 2011-2020
Table 81: PD Therapeutics Market, Japan, Treatment Usage Patterns, 2011-2020
Table 82: PD Therapeutics Market,Japan, Drug Sales ($m), 2002-2011
Table 83: PD Therapeutics Market,Spain, Drug Sales ($m), 2011-2020
Table 84: PD Therapeutics Market, Brazil, Sales Value ($m), 2002-2011
Table 85: PD Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002-2011
Table 86: PD Therapeutics Market, Brazil, Patient Volume (Absolute), 2002-2011
Table 87: PD Therapeutics Market, Brazil, Treatment Usage Patterns, 2002-2011
Table 88: PD Therapeutics Market, Brazil, Sales Value ($m), 2011-2020
Table 89: PD Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011-2020
Table 90: PD Therapeutics Market, Brazil, Patient Volume (Absolute), 2011-2020
Table 91: PD Therapeutics Market, Brazil, Treatment Usage Patterns, 2011-2020
Table 92: PD Therapeutics Market, India, Sales Value ($m), 2002-2011
Table 93: PD Therapeutics Market, India, Annual Cost of Therapy ($), 2002-2011
Table 94: PD Therapeutics Market, India, Patient Volume (Absolute), 2002-2011
Table 95: PD Therapeutics Market, India, Treatment Usage Patterns, 2002-2011
Table 96: PD Therapeutics Market, India, Sales Value ($m), 2011-2020
Table 97: PD Therapeutics Market, India, Annual Cost of Therapy ($), 2011-2020
Table 98: PD Therapeutics Market, India, Patient Volume (Absolute), 2011-2020
Table 99: PD Therapeutics Market, India, Treatment Usage Patterns, 2011-2020
Table 100: PD Therapeutics Market, China, Sales Value ($m), 2002-2011
Table 101: PD Therapeutics Market, China, Annual Cost of Therapy ($), 2002-2011
Table 102: PD Therapeutics Market, China, Patient Volume (Absolute), 2002-2011
Table 103: PD Therapeutics Market, China, Treatment Usage Patterns, 2002-2011
Table 104: PD Therapeutics Market, China, Sales Value ($m), 2011-2020
Table 105: PD Therapeutics Market, China, Annual Cost of Therapy ($), 2011-2020
Table 106: PD Therapeutics Market, China, Patient Volume (Absolute), 2011-2020
Table 107: PD Therapeutics Market, China, Treatment Usage Patterns, 2011-2020
Table 108: PD Therapeutics Market, Russia, Sales Value ($m), 2002-2011
Table 109: PD Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002-2011
Table 110: PD Therapeutics Market, Russia, Patient Volume (Absolute), 2002-2011
Table 111: PD Therapeutics Market, Russia, Treatment Usage Patterns, 2002-2011
Table 112: PD Therapeutics Market, Russia, Sales Value ($m), 2011-2020
Table 113: PD Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011-2020
Table 114: PD Therapeutics Market, Russia, Patient Volume (Absolute), 2011-2020
Table 115: PD Therapeutics Market, Russia, Treatment Usage Patterns, 2011-2020
Table 116: Major Marketed Products Comparison in the PD Market, 2011
Table 117: Promising Drugs Under Clinical Development, 2011
Table 118: PD Therapeutics, Filed and Phase III Pipeline Products, 2011
Table 119: PD Therapeutics, Phase II Pipeline Products, 2011
Table 120: PD Therapeutics, Phase I Pipeline Products, 2011
Table 121: PD Therapeutics, Preclinical/Discovery Pipeline Products, 2011
Table 122: PD Therapeutics Market, Global, Clinical Trials by Status, January, 2012
Table 123: PD Therapeutics Market, Global, Clinical Trials by Country, January, 2012
Table 124: PD Therapeutics Market, Global, Clinical Trials by Phase, January, 2012
Table 125: PD Therapeutics Market, Global, Clinical Trials by Sponsor Type, January, 2012
Table 126: PD Therapeutics Market, Global, Clinical Trials, Leading Sponsors, January, 2012
Table 127: PD Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, January, 2012
Table 128: PD Therapeutics Market, Global, Average Number of Patients Recruited, January, 2012
Table 129: Abbott Laboratories CNS Pipeline
Table 130: Acadia Pharmaceutical CNS Pipeline
Table 131: Merck CNS Pipeline
Table 132: Impax Laboratories CNS Pipeline
Table 133: Newron Pharmaceuticals S.p.A CNS Pipeline
Table 134: PD Therapeutics Market, Global, M&A Deals, 2010-2011
1.2 List of Figures
Figure 1: Dopamine Levels in Normal and Parkinson Affected Neurons
Figure 2: PD Prevalence in The US and Europe
Figure 3: Split of PD Patients by Mild, Moderate and Severe
Figure 4: Factors Involved in PD
Figure 5: Pathogenesis of PD
Figure 6: Motor Features of PD
Figure 7: Non Motor Features of PD
Figure 8: Mortality/Severe Disability Rate due to PD before Introduction of Levodopa
Figure 9: Positron Emission Tomography (PET) (A) and Single Photon Emission Computerized Tomography (SPECT) (B) Brain Images of Normal and PD Patients
Figure 10: Therapeutic Choice for PD
Figure 11: Management of PD - Treatment Algorithm
Figure 12: Medications used for Treating PD
Figure 13: Mode of Action of PD Therapies
Figure 14: PD Therapeutics Market, Global, Sales Value ($m), 2002-2011
Figure 15: PD Therapeutics Market, Global, Sales Value ($m) by Country, 2002-2011
Figure 16: PD Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2011
Figure 17: PD Therapeutics Market, Global, Patient Volume (Absolute), 2002-2011
Figure 18: PD Therapeutics Market, Global, Treatment Usage Patterns, 2002-2011
Figure 19: PD Therapeutics Market, Global, Market Drivers and Restraints, 2011
Figure 20: PD Therapeutics Market, Global, Impact of Historical Events on the Market, 2011
Figure 21: PD Therapeutics Market, Global, Sales Value ($m), 2011-2020
Figure 22: PD Therapeutics Market, Global, Sales Value ($m) by Country, 2011-2020
Figure 23: PD Therapeutics Market, Global, Annual Cost of Therapy ($), 2011-2020
Figure 24: PD Therapeutics Market, Global, Patient Volume (Absolute), 2011-2020
Figure 25: PD Therapeutics Market, Global, Treatment Usage Patterns, 2011-2020
Figure 26: PD Therapeutics Market, Global, Future Market Drivers and Restraints, 2011-2020
Figure 27: PD Therapeutics Market, Global, Drug Sales ($m), 2002-2020
Figure 28: PD Therapeutics Market, The US, Sales Value ($m), 2002-2011
Figure 29: PD Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2011
Figure 30: PD Therapeutics Market, The US, Patient Volume (Absolute), 2002-2011
Figure 31: PD Therapeutics Market, The US, Treatment Usage Patterns, 2002-2011
Figure 32: PD Therapeutics Market, The US, Market Drivers and Restraints, 2011
Figure 33: PD Therapeutics Market, The US, The Impact of Historical Events on the Market, 2011
Figure 34: PD Therapeutics Market, The US, Sales Value ($m), 2011-2020
Figure 35: PD Therapeutics Market, The US, Annual Cost of Therapy ($), 2011-2020
Figure 36: PD Therapeutics Market, The US, Patient Volume (Absolute), 2011-2020
Figure 37: PD Therapeutics Market, The US, Treatment Usage Patterns, 2011-2020
Figure 38: PD Therapeutics Market, The US, Future Market Drivers and Restraints, 2011-2020
Figure 39: PD Therapeutics Market, The US, Drug Sales ($m), 2002-2020
Figure 40: PD Therapeutics Market, The UK, Sales Value ($m), 2002-2011
Figure 41: PD Therapeutics Market, The UK, Annual Cost of Therapy ($), 2002-2011
Figure 42: PD Therapeutics Market, The UK, Patient Volume (Absolute), 2002-2011
Figure 43: PD Therapeutics Market, The UK, Treatment Usage Patterns, 2002-2011
Figure 44: PD Therapeutics Market, The UK, Market Drivers and Restraints, 2011
Figure 45: PD Therapeutics Market, The UK, The Impact of Historical Events on the Market, 2011
Figure 46: PD Therapeutics Market, The UK, Sales Value ($m), 2011-2020
Figure 47: PD Therapeutics Market, The UK, Annual Cost of Therapy ($), 2011-2020
Figure 48: PD Therapeutics Market, The UK, Patient Volume (Absolute), 2011-2020
Figure 49: PD Therapeutics Market, The UK, Treatment Usage Patterns, 2011-2020
Figure 50: PD Therapeutics Market, The UK, Future Market Drivers and Restraints, 2011-2020
Figure 51: PD Therapeutics Market, The UK, Drug Sales ($m), 2002-2020
Figure 52: PD Therapeutics Market, Germany, Sales Value ($m), 2002-2011
Figure 53: PD Therapeutics Market, Germany, Annual Cost of Therapy ($), 2002-2011
Figure 54: PD Therapeutics Market, Germany, Patient Volume (Absolute), 2002-2011
Figure 55: PD Therapeutics Market, Germany, Treatment Usage Patterns, 2002-2011
Figure 56: PD Therapeutics Market, Germany, Market Drivers and Restraints, 2011
Figure 57: PD Therapeutics Market, Germany, The Impact of Historical Events on the Market, 2011
Figure 58: PD Therapeutics Market, Germany, Sales Value ($m), 2011-2020
Figure 59: PD Therapeutics Market, Germany, Annual Cost of Therapy ($), 2011-2020
Figure 60: PD Therapeutics Market, Germany, Patient Volume (Absolute), 2011-2020
Figure 61: PD Therapeutics Market, Germany, Treatment Usage Patterns, 2011-2020
Figure 62: PD Therapeutics Market, Germany, Future Market Drivers and Restraints, 2011-2020
Figure 63: PD Therapeutics Market, Germany, Drug Sales ($m), 2002-2020
Figure 64: PD Therapeutics Market, France, Sales Value ($m), 2002-2011
Figure 65: PD Therapeutics Market, France, Annual Cost of Therapy ($), 2002-2011
Figure 66: PD Therapeutics Market, France, Patient Volume (Absolute), 2002-2011
Figure 67: PD Therapeutics Market, France, Treatment Usage Patterns, 2002-2011
Figure 68: PD Therapeutics Market, France, Market Drivers and Restraints, 2011
Figure 69: PD Therapeutics Market, France, The Impact of Historical Events on the Market, 2011
Figure 70: PD Therapeutics Market, France, Sales Value ($m), 2011-2020
Figure 71: PD Therapeutics Market, France, Annual Cost of Therapy ($), 2011- 2020
Figure 72: PD Therapeutics Market, France, Patient Volume (Absolute), 2011-2020
Figure 73: PD Therapeutics Market, France, Treatment Usage Patterns, 2011-2020
Figure 74: PD Therapeutics Market, France, Future Market Drivers and Restraints, 2011-2020
Figure 75: PD Therapeutics Market, France, Drug Sales ($m), 2002-2020
Figure 76: PD Therapeutics Market, Italy, Sales Value ($m), 2002-2011
Figure 77: PD Therapeutics Market, Italy, Annual Cost of Therapy ($), 2002-2011
Figure 78: PD Therapeutics Market, Italy, Patient Volume (Absolute), 2002-2011
Figure 79: PD Therapeutics Market, Italy, Treatment Usage Patterns, 2002-2011
Figure 80: PD Therapeutics Market, Italy, Market Drivers and Restraints, 2011
Figure 81: PD Therapeutics Market, Italy, The Impact of Historical Events on the Market, 2011
Figure 82: PD Therapeutics Market, Italy, Sales Value ($m), 2011-2020
Figure 83: PD Therapeutics Market, Italy, Annual Cost of Therapy ($), 2011-2020
Figure 84: PD Therapeutics Market, Italy, Patient Volume (Absolute), 2011-2020
Figure 85: PD Therapeutics Market, Italy, Treatment Usage Patterns, 2011-2020
Figure 86: PD Therapeutics Market, Italy, Future Market Drivers and Restraints, 2011-2020
Figure 87: PD Therapeutics Market, Italy, Drug Sales ($m), 2002-2020
Figure 88: PD Therapeutics Market, Spain, Sales Value ($m), 2002-2011
Figure 89: PD Therapeutics Market, Spain, Annual Cost of Therapy ($), 2002-2011
Figure 90: PD Therapeutics Market, Spain, Patient Volume (Absolute), 2002-2011
Figure 91: PD Therapeutics Market, Spain, Treatment Usage Patterns, 2002-2011
Figure 92: PD Therapeutics Market, Spain, Market Drivers and Restraints, 2011
Figure 93: PD Therapeutics Market, Spain, The Impact of Historical Events on the Market, 2011
Figure 94: PD Therapeutics Market, Spain, Sales Value ($m), 2011-2020
Figure 95: PD Therapeutics Market, Spain, Annual Cost of Therapy ($), 2011-2020
Figure 96: PD Therapeutics Market, Spain, Patient Volume (Absolute), 2011-2020
Figure 97: PD Therapeutics Market, Spain, Treatment Usage Patterns, 2011-2020
Figure 98: PD Therapeutics Market, Spain, Future Market Drivers and Restraints, 2011-2020
Figure 99: PD Therapeutics Market, Spain, Drug Sales ($m), 2002-2020
Figure 100: PD Therapeutics Market, Japan, Sales Value ($m), 2002-2011
Figure 101: PD Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2011
Figure 102: PD Therapeutics Market, Japan, Patient Volume (Absolute), 2002-2011
Figure 103: PD Therapeutics Market, Japan, Treatment Usage Patterns, 2002-2011
Figure 104: PD Therapeutics Market, Japan, Market Drivers and Restraints, 2011
Figure 105: PD Therapeutics Market, Japan, The Impact of Historical Events on the Market, 2011
Figure 106: PD Therapeutics Market, Japan, Sales Value ($m), 2011-2020
Figure 107: PD Therapeutics Market, Japan, Annual Cost of Therapy ($), 2011-2020
Figure 108: PD Therapeutics Market, Japan, Patient Volume (Absolute), 2011-2020
Figure 109: PD Therapeutics Market, Japan, Treatment Usage Patterns, 2011-2020
Figure 110: PD Therapeutics Market, Japan, Future Market Drivers and Restraints, 2011-2020
Figure 111: PD Therapeutics Market, Japan, Drug Sales ($m), 2002-2020
Figure 112: PD Therapeutics Market, Brazil, Sales Value ($m), 2002-2011
Figure 113: PD Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2002-2011
Figure 114: PD Therapeutics Market, Brazil, Patient Volume (Absolute), 2002-2011
Figure 115: PD Therapeutics Market, Brazil, Treatment Usage Patterns, 2002-2011
Figure 116: PD Therapeutics Market, Brazil, Market Drivers and Restraints, 2011
Figure 117: PD Therapeutics Market, Brazil, The Impact of Historical Events on the Market, 2011
Figure 118: PD Therapeutics Market, Brazil, Sales Value ($m), 2011-2020
Figure 119: PD Therapeutics Market, Brazil, Annual Cost of Therapy ($), 2011-2020
Figure 120: PD Therapeutics Market, Brazil, Patient Volume (Absolute), 2011-2020
Figure 121: PD Therapeutics Market, Brazil, Treatment Usage Patterns, 2011-2020
Figure 122: PD Therapeutics Market, Brazil, Future Market Drivers and Restraints, 2011-2020
Figure 123: PD Therapeutics Market, India, Sales Value ($m), 2002-2011
Figure 124: PD Therapeutics Market, India, Annual Cost of Therapy ($), 2002-2011
Figure 125: PD Therapeutics Market, India, Patient Volume (Absolute), 2002-2011
Figure 126: PD Therapeutics Market, India, Treatment Usage Patterns, 2002-2011
Figure 127: PD Therapeutics Market, India, Market Drivers and Restraints, 2011
Figure 128: PD Therapeutics Market, India, The Impact of Historical Events on the Market, 2011
Figure 129: PD Therapeutics Market, India, Sales Value ($m), 2011-2020
Figure 130: PD Therapeutics Market, India, Annual Cost of Therapy ($), 2011-2020
Figure 131: PD Therapeutics Market, India, Patient Volume (Absolute), 2011-2020
Figure 132: PD Therapeutics Market, India, Treatment Usage Patterns, 2011-2020
Figure 133: PD Therapeutics Market, India, Future Market Drivers and Restraints, 2011-2020
Figure 134: PD Therapeutics Market, China, Sales Value ($m), 2002-2011
Figure 135: PD Therapeutics Market, China, Annual Cost of Therapy ($), 2002-2011
Figure 136: PD Therapeutics Market, China, Patient Volume (Absolute), 2002-2011
Figure 137: PD Therapeutics Market, China, Treatment Usage Patterns, 2002-2011
Figure 138: PD Therapeutics Market, China, Market Drivers and Restraints, 2011
Figure 139: PD Therapeutics Market, China, The Impact of Historical Events on the Market, 2011
Figure 140: PD Therapeutics Market, China, Sales Value ($m), 2011-2020
Figure 141: PD Therapeutics Market, China, Annual Cost of Therapy ($), 2011-2020
Figure 142: PD Therapeutics Market, China, Patient Volume (Absolute), 2011-2020
Figure 143: PD Therapeutics Market, China, Treatment Usage Patterns, 2011-2020
Figure 144: PD Therapeutics Market, China, Future Market Drivers and Restraints, 2011-2020
Figure 145: PD Therapeutics Market, Russia, Sales Value ($m), 2002-2011
Figure 146: PD Therapeutics Market, Russia, Annual Cost of Therapy ($), 2002-2011
Figure 147: PD Therapeutics Market, Russia, Patient Volume (Absolute), 2002-2011
Figure 148: PD Therapeutics Market, Russia, Treatment Usage Patterns, 2002-2011
Figure 149: PD Therapeutics Market, Russia, Market Drivers and Restraints, 2011
Figure 150: PD Therapeutics Market, Russia, The Impact of Historical Events on the Market, 2011
Figure 151: PD Therapeutics Market, Russia, Sales Value ($m), 2011-2020
Figure 152: PD Therapeutics Market, Russia, Annual Cost of Therapy ($), 2011-2020
Figure 153: PD Therapeutics Market, Russia, Patient Volume (Absolute), 2011-2020
Figure 154: PD Therapeutics Market, Russia, Treatment Usage Patterns, 2011-2020
Figure 155: PD Therapeutics Market, Russia, Future Market Drivers and Restraints, 2011-2020
Figure 156: Opportunity and Unmet Need in the in the PD Therapeutics Market, 2011
Figure 157: Strategic Competitor Assessment of the Major Marketed Products in PD, 2011
Figure 158: PD Therapeutics Market, Global, Stalevo, Sales Forecast 2002-2020
Figure 159: PD Therapeutics Market, Global, Stalevo, Market Share (%) 2011
Figure 160: PD Therapeutics Market, Global, Requip/Requip XL, Sales Forecast 2002-2020
Figure 161: PD Therapeutics Market, Global, Requip/Requip XL, Market Share (%) 2011
Figure 162: PD Therapeutics Market, Global, Azilect, Sales Forecast 2002-2020
Figure 163: PD Therapeutics Market, Global, Azilect, Market Share (%) 2011
Figure 164: PD Therapeutics Market, Global, Mirapex/Mirapex ER, Sales Forecast 2002-2020
Figure 165: PD Therapeutics Market, Global, Mirapex/Mirapex ER , Market Share (%) 2011
Figure 166: PD Therapeutics Market, Global, Comtan, Sales Forecast 2002-2020
Figure 167: PD Therapeutics Market, Global, Comtan , Market Share (%) 2011
Figure 168: PD Therapeutics Market, Global, Neupro, Sales Forecast 2002-2020
Figure 169: PD Therapeutics Market, Global, Neupro , Market Share (%) 2011
Figure 170: PD Therapeutics Market, Global, Apokyn, Sales Forecast 2002-2020
Figure 171: Technology Trends Analytic Framework of the PD Pipeline, 2011
Figure 172: Technology Trends Analytic Framework Description of the PD Pipeline, 2011
Figure 173: PD Therapeutics Market, Global, IPX 066 , Sales Forecast ($m), 2013-2020
Figure 174: PD Therapeutics Market, Global, Safinamide, Sales Forecast ($m), 2013-2020
Figure 175: PD Therapeutics Market, Global, Preladenant, Sales Forecast ($m), 2013-2020
Figure 176: PD Therapeutics Market - Clinical Pipeline by Mechanism of Action, 2011
Figure 177: PD Therapeutics Market - Pipeline by Clinical Phase of Development
Figure 178: PD Therapeutics Market, Global, Clinical Trials by Status, January, 2012
Figure 179: PD Therapeutics Market, Global, Clinical Trials by Country, January, 2012
Figure 180: PD Therapeutics Market, Global, Clinical Trials by Phase, January, 2012
Figure 181: PD Therapeutics Market, Global, Clinical Trials by Sponsor Type, January, 2012
Figure 182: PD Therapeutics Market, Global, Clinical Trials, Leading Company Sponsors, January, 2012
Figure 183: PD Therapeutics Market, Global, Clinical Trials, Average Number of Patients Recruited, January, 2012
Figure 184: Implications for Future Market Competition in the PD Market, 2011
Figure 185: PD, Global, Abbott Laboratories, SWOT Analysis 2010
Figure 186: PD, Global, Acadia Pharmaceuticals, SWOT Analysis 2010
Figure 187: PD, Global, Merck & Co., SWOT Analysis 2010
Figure 188: PD, Global, Impax Laboratories, SWOT Analysis 2010
Figure 189: PD, Global, Newron Pharmaceuticals S.p.A, SWOT Analysis 2010
Figure 190: Parkinson’s Disease, The US, Key Data Inputs from KOL Interviews, August 2011
Figure 191: Parkinson’s Disease, France, Key Data Inputs from KOL Interviews, August 2011
Figure 192: Parkinson’s Disease, Germany, Key Data Inputs from KOL Interviews, August 2011
Figure 193: Parkinson’s Disease, The UK, Key Data Inputs from KOL Interviews, August 2011
Figure 194: Parkinson’s Disease, Italy, Key Data Inputs from KOL Interviews, August 2011
Figure 195: Parkinson’s Disease, India, Key Data Inputs from KOL Interviews, August 2011
Figure 196: GlobalData Market Forecasting Model
GlobalData has released its pharma report, “Parkinson’s Disease Therapeutics - Global Drug Forecasts and Treatment Analysis to 2020”. The report is an essential source of information and analysis on the global Parkinson’s disease Therapeutics therapeutics market. The report provides comprehensive information on Parkinson’sDisease Therapeutics, highlighting the treatment guidelines. It identifies and analyses the key trends shaping and driving the global Parkinson’s Disease Therapeutics therapeutics market. It analyses the treatment usage patterns in the global Parkinson’s Disease Therapeutics therapeutics market. The report also provides insights into the competitive landscape and the emerging players expected to significantly alter the positions of the existing market leaders. The report provides valuable insights into the pipeline products within the global Parkinson’s Disease Therapeutics sector. It quantifies the unmet need in the global Parkinson’s Disease Therapeutics therapeutics market as well as in the individual markets such as the US and the top five countries in Europe, highlighting the opportunity for future players. This report is built using data and information sourced from proprietary databases, primary and secondary research.
Parkinson’s Disease (PD) Therapeutics Market is Forecast to Show Slow Growth to 2020
In 2011, the global Parkinson’s Disease (PD) therapeutics market, which includes the key markets of the US, Japan, Germany, the UK, France, Italy, Spain, Brazil, China, India and Russia was estimated to be worth $2,992m. During the period 2002-2011, the global PD therapeutics market grew at a Compound Annual Growth Rate (CAGR) of 5.8%. GlobalData analysis shows that the market size was primarily driven by two key parameters: the increase in PD prevalence due to the increase in the aging population in the 11 key markets and the increasing cost of therapy.
In 2011, the market registered a decline in the market valuations due to the entry of generics for Mirapex (pramipexole) and higher preference for generic ropinirole. The market declined from $3,499m in 2010 to $2,992m in 2011. The US was leading PD therapeutics market, with an estimated value of $1,046m in 2011 and a market share of 35%. Japan was the second biggest market, with an estimated value of $542m and an 18.1% market share, followed by Germany with a market share of 15.6%.
The global PD therapeutics market is primarily served by levodopa, dopamine agonists, Monoamine Oxidase Inhibitors (MAO-BI) and Catechol-O-Methyltransferase (COMT) inhibitors. The market is dominated by branded products such as Boehringer Ingelheim’s Mirapex/Mirapexin / Sifrol / Mirapex ER / Mirapexin ER (pramipexole), GlaxoSmithKline’s (GSK) Requip/Requip XL (ropinirole), Orion / Novartis’ Stalevo/Comtan (carbidopa/levodopa/entacapone) and Teva/Lundbeck’s Azilect/Agilect (rasagiline). In addition, a large number of generics are also available in this market.
In 2011, the top three drugs in the G7 markets (the US, Japan, Germany, the UK, Spain, France, and Italy) were Stalevo/Comtan, Mirapex, and Azilect with annual sales of $688.2m, $567.8m and $323.5m respectively.
The global PD therapeutics market is expected to grow at a modest CAGR of 2.2% and is forecast to reach $3,650m by 2020. This modest growth rate is due to the patent expiries of major drugs, the subsequent entry of generics and the weak, late-stage developmental pipeline. The major drugs, which are expected go off patent during this period are Azilect, Comtan, Stalevo, Tasmar, Mirapex ER and Requip XL, of which the impact is expected to be partially adjusted by the introduction of new drugs such as IPX 066, preladenant and safinamide during 2011-2020.
Abbott Laboratories
ACADIA Pharmaceuticals Inc
Merck & Co.
IMPAX Laboratories
Newron Pharmaceuticals S.p.A
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
